Study on Drug Optimization for Patients with Comorbid Hypertension and Coronary Heart Disease

Abstract

Comorbidity of hypertension and coronary heart disease (CHD) is a common and complex clinical condition, making drug treatment optimization crucial. Hypertension accelerates the development of CHD by promoting atherosclerosis and cardiac structural changes. Current pharmacological treatments include diuretics, ACE inhibitors, calcium channel blockers, and β-adrenergic antagonists for hypertension, as well as antiplatelet agents, statins, β-adrenergic antagonists, and ACE inhibitors for CHD. Drug optimization strategies involve individualized treatment, optimization of polypharmacy, and dynamic adjustment. Future directions focus on the development of innovative drugs and treatment methods, data-driven drug optimization techniques, and multidisciplinary collaboration models. These advancements will enhance the precision and effectiveness of drug therapy, thereby improving the overall health and quality of life of patients.